Els professionals de l\u2019oncologia m\u00e8dica s\u2019afronten sovint al repte de tractar pacients amb c\u00e0ncer avan\u00e7at que no responen als tractaments habituals i s\u2019han quedat sense opcions terap\u00e8utiques aprovades. Per superar aquest escull d\u2019una manera m\u00e9s r\u00e0pida, investigadors d\u2019arreu del m\u00f3n avancen en la recerca de la reutilitzaci\u00f3 de medicaments pr\u00e8viament aprovats per a una altra indicaci\u00f3, i els resultats que s\u2019obtenen ja estan accelerant, a dia d\u2019avui, la seva aplicaci\u00f3 en oncologia. El fet, precisament, de tractar-se de f\u00e0rmacs ja aprovats porta impl\u00edcit que la seva seguretat ja \u00e9s coneguda, i aix\u00f2 en facilita el desenvolupament per a una nova indicaci\u00f3.<\/p>\n
Un treball recent co-liderat pel Dr. Albert Antol\u00edn, investigador del programa Oncobell de l\u2019IDIBELL i del programa ProCure de l\u2019ICO, i pel Dr. Malaka Ameratunga, del Department d\u2019oncologia m\u00e8dica del The Alfred Hospital i la Monash University de Melbourne (Australi\u00e0), ha demostrat que l\u2019estrat\u00e8gia combinada de l\u2019an\u00e0lisi de biomarcadors dels pacients i la cerca computacional de f\u00e0rmacs reutilitzables permet identificar ter\u00e0pies aplicables a pacients que a dia d\u2019avui no tindrien tractament.<\/p>\n
Els resultats de la seva recerca, publicats a la revista Clinical and Translational Medicine<\/em>, s\u2019han obtingut mitjan\u00e7ant la seq\u00fcenciaci\u00f3 gen\u00f2mica de nova generaci\u00f3 d\u2019un total de 94 pacients, amb l\u2019objectiu d\u2019analitzar-ne diversos biomarcadors. D\u2019aquests, l\u2019abordatge computacional del reaprofitament de f\u00e0rmacs prediu que un significatiu percentatge del 14 % podrien tractar-se amb ter\u00e0pies ja aprovades per la Food and Drug Administration (FDA) i que actualment s\u2019apliquen a malalties diferents.<\/p>\n Tot i que ser\u00e0 necess\u00e0ria la realitzaci\u00f3 d\u2019estudis addicionals que ho confirmin, l\u2019enfocament computacional de reutilitzaci\u00f3 de f\u00e0rmacs pot ajudar a identificar de forma precisa nous tractaments per a pacients amb c\u00e0ncer que no responen a les ter\u00e0pies est\u00e0ndard, la qual cosa acceleraria l\u2019ampliaci\u00f3 de les indicacions aprovades d\u2019aquests medicaments per beneficiar un nombre major de pacients.<\/p>\n <\/p>\n L\u2019Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l\u2019Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l\u2019Institut Catal\u00e0 de la Salut, l\u2019Institut Catal\u00e0 d\u2019Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n L\u2019IDIBELL \u00e9s membre del Campus d\u2019Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L\u2019any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n <\/p>\n","protected":false},"excerpt":{"rendered":" L\u2019abordatge computacional del reaprofitament de f\u00e0rmacs prediu que un significatiu percentatge del 14 % del pacients podrien tractar-se amb ter\u00e0pies ja aprovades<\/p>\n","protected":false},"author":8,"featured_media":25453,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"set","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452,519],"tags":[],"class_list":["post-25452","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure","category-quimica-medica-i-disseny-de-farmacs"],"publishpress_future_action":{"enabled":false,"date":"2024-12-29 08:00:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/25452","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=25452"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/25452\/revisions"}],"predecessor-version":[{"id":25454,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/25452\/revisions\/25454"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/25453"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=25452"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=25452"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=25452"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}